Antihistamine is a type of drug that blocks the action of histamines, which can cause fever, itching, sneezing, a runny nose, and watery eyes. Antihistamines are used to prevent fevers in patients receiving blood transfusions and to treat allergies, coughs, and colds.
In addition to a skin rash, many eczema sufferers also experience chronic itching, but sometimes that itching can become torturous. Worse, antihistamines -- the standard treatment for itching and allergy -- often don't help.
In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.
For hay fever sufferers, spring means sneezing, itchy eyes and a runny nose. Medicines can bring some relief to these symptoms, and some medicines can help prevent the symptoms if taken regularly.
Scientists have described a potential new therapeutic strategy for slowing down early-stage Huntington's disease in a new study published today in eLife.
Cheryl Morales started the medicinal garden at the Aaniiih Nakoda College demonstration farm with only four plants: yarrow, echinacea, plantain and licorice root.
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma? A new study from Lund University in Sweden indicates that this may be the case.
A new study published in February 2020, in the journal Nature Neuroscience, shows that short-term learning occurs rapidly, but for it to become a long-term memory, brain cells must form more myelin, an insulating fatty material.
Perhaps you think of allergies as being most bothersome- and most likely to occur- during the spring and summer months, when pollens and molds are seemingly everywhere.
By all accounts the woman, in her late 60s, appeared to have severe dementia. She was largely incoherent. Her short-term memory was terrible. She couldn't focus on questions that medical professionals asked her.
When doctors told Frances Faulkenburg she had sleep apnea, she was more than ready for relief from her tired-all-the-time existence. She used to fall asleep at red lights while behind the wheel. At night, she'd wake up gasping for air, heart pounding. Her husband told her she snored.
Hesperos Inc., pioneers of the "human-on-a-chip" in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known cardiotoxic small molecules over time, to accurately describe the drug behavior and toxic effects in vivo.
Glioblastoma is the most prevalent and also the most lethal type of brain tumor in adults, with no curative treatment currently available.
The U.S. Food and Drug Administration today approved Benlysta (belimumab) intravenous infusion for treatment of children with systemic lupus erythematosus – often referred to as simply "lupus" – a serious chronic disease that causes inflammation and damage to various body tissues and organs.
Williams Syndrome, a rare neurodevelopmental disorder that affects about one in 10,000 babies born in the United States, produces a range of symptoms including cognitive impairments, cardiovascular problems, and extreme friendliness, or hypersociability.
A team of scientists headed by Maik Behrens from the Leibniz-Institute for Food Systems Biology at the Technical University of Munich has identified the receptor responsible for the bitter taste of various salts. These include medically used Epsom salt.
Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.
Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.
A recent study shows that a new eye drop may be a potentially effective treatment for seasonal eye allergies, a condition affecting millions of people worldwide.
"Ladies and gentlemen, is there a physician on board?" The flight attendant on a flight from Rwanda to Turkey made the announcement no one wants to hear, and Rachel Zang, MD, an Emergency Medicine resident at the Hospital of the University of Pennsylvania, jumped into action.